[CA-MRSA].
Iwata
Kentaro
K
Department of General Medicine and Infectious Diseases, Kameda Medical Center.
D000081:Acetamides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000235:genetics; D001427:Bacterial Toxins; D002876:Chromosomes, Bacterial / Q000235:genetics; D002981:Clindamycin / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D005098:Exotoxins; D006801:Humans; D007956:Leukocidins; D000069349:Linezolid; D016106:Methicillin Resistance / Q000235:genetics; D023303:Oxazolidinones / Q000627:therapeutic use; D046915:Penicillin-Binding Proteins; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification / Q000472:pathogenicity
D000081:Acetamides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D005098:Exotoxins; D007956:Leukocidins; D023303:Oxazolidinones; C078284:Panton-Valentine leukocidin; D046915:Penicillin-Binding Proteins; C487789:mecA protein, Staphylococcus aureus; D002981:Clindamycin; D000069349:Linezolid